Bank of America’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.6M | Buy |
643,000
+21,650
| +3% | +$339K | ﹤0.01% | 3001 |
|
|
2025
Q4 | $11.3M | Buy |
621,350
+15,508
| +3% | +$262K | ﹤0.01% | 2758 |
|
|
2025
Q3 | $7.7M | Buy |
605,842
+199,271
| +49% | +$1.71M | ﹤0.01% | 3574 |
|
|
2025
Q2 | $2.03M | Buy |
406,571
+400,898
| +7,067% | +$1.87M | ﹤0.01% | 4762 |
|
|
2025
Q1 | $45.4K | Buy |
5,673
+3
| +0.1% | +$23 | ﹤0.01% | 6777 |
|
|
2024
Q4 | $42.1K | Buy |
5,670
+69
| +1% | +$738 | ﹤0.01% | 6674 |
|
|
2024
Q3 | $53.2K | Hold |
5,601
| – | – | ﹤0.01% | 6522 |
|
|
2024
Q2 | $69.8K | Buy |
+5,601
| New | +$72.7K | ﹤0.01% | 6407 |
|
|
2023
Q3 | – | Sell |
-17
| Closed | -$1.47K | – | 7767 |
|
|
2023
Q2 | $1.47K | Sell |
17
-1
| -6% | -$673 | ﹤0.01% | 7193 |
|
|
2023
Q1 | $7.54K | Buy |
+18
| New | +$14.2K | ﹤0.01% | 6983 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 7790 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 7818 |
|
|
2022
Q2 | – | Sell |
-1
| Closed | -$1.34K | – | 7999 |
|
|
2022
Q1 | $3K | Sell |
1
-8
| -89% | -$20.1K | ﹤0.01% | 7968 |
|
|
2021
Q4 | $46K | Sell |
9
-7
| -44% | -$42K | ﹤0.01% | 7254 |
|
|
2021
Q3 | $102K | Buy |
16
+14
| +700% | +$113K | ﹤0.01% | 6711 |
|
|
2021
Q2 | $16K | Sell |
2
-9
| -82% | -$75.4K | ﹤0.01% | 7190 |
|
|
2021
Q1 | $96K | Buy |
11
+7
| +175% | +$66.1K | ﹤0.01% | 6405 |
|
|
2020
Q4 | $29K | Buy |
4
+3
| +300% | +$20.8K | ﹤0.01% | 6494 |
|
|
2020
Q3 | $8K | Sell |
1
-2
| -67% | -$15K | ﹤0.01% | 6497 |
|
|
2020
Q2 | $19K | Buy |
3
+2
| +200% | +$14.5K | ﹤0.01% | 6276 |
|
|
2020
Q1 | $10K | Sell |
1
-1
| -50% | -$10.6K | ﹤0.01% | 6356 |
|
|
2019
Q4 | $32K | Sell |
2
-1
| -33% | -$10.5K | ﹤0.01% | 6391 |
|
|
2019
Q3 | $31K | Buy |
3
+2
| +200% | +$22.3K | ﹤0.01% | 6477 |
|
|
2019
Q2 | $23K | Sell |
1
-1
| -50% | -$15.2K | ﹤0.01% | 6535 |
|
|
2019
Q1 | $37K | Buy |
+2
| New | +$29.9K | ﹤0.01% | 6304 |
|
|
2018
Q2 | – | Hold |
0
| – | -$1K | – | 7074 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6947 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6924 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6955 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7026 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6801 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | -$18.2K | – | 7114 |
|
|
2016
Q1 | $18K | Buy |
+2
| New | +$19.8K | ﹤0.01% | 6171 |
|
Other funds holding AVTX
CP
BI
ACA
AAA
NCM
FCM
Bank of America's AVTX Position: Q1 2026 in Review
Bank of America increased its Avalo Therapeutics (AVTX) stake by 3.5% in Q1 2026, buying an estimated $339K and bringing the position to 643,000 shares worth $9.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3001.
Bank of America first reported a position in AVTX in Q1 2016 and has held it in 24 quarters since. The position peaked at $11.3M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.
- Bank of America held 643,000 shares of Avalo Therapeutics worth $9.6M as of Q1 2026.
- Bank of America bought 21,650 Avalo Therapeutics shares in Q1 2026, an estimated $339K.
- Avalo Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3001 holding.
- Bank of America first reported a position in Avalo Therapeutics in Q1 2016 and has held it in 24 quarters since.
- Bank of America's Avalo Therapeutics position peaked at $11.3M in Q4 2025.
- 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.